Ziphius
ActiveSummary
The annual accounts of Ziphius for financial year 2025 show a net loss of 124% of total assets and of 94% of the equity at the start of that year. The 2025 annual accounts show equity of €5.9m and a net result of -€11.8m. Equity is shrinking by about 34% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2027. Its solvency ranks better than 75% of 60 sector peers (NACE 21, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.6% (low).
Directors
Board 6
Day-to-day management 2
Permanent representatives 3
Statutory auditor 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- Statutory auditor
- began earlier
| Name | Functions and periods |
|---|---|
| Van Hoof Biotech and Business Services |
|
| Margareta Nuytinck |
|
| CARDON BIO |
|
| Geertrui Vanhove |
|
| JoB.Bio.com |
|
| SAIGA PHARMAfrom an act |
|
| PricewaterhouseCoopers Reviseurs d'Entreprises |
|
| RNA Pioneering |
|
| Post Verba Verbera NV |
|
Owners and capital
Owners
2 ownersChain of control
- RNA Pioneering
- Ziphius
Highest known parent: RNA Pioneering. The sources do not say who stands above it.
Owners 2
- RNA Pioneeringparent58.99%
-
15.02%
According to the 2025 annual accounts of Ziphius and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- Investeerders 10,419 shares
- RNA Pioneering NV (BE 0456.792.695)
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
- 08-06-2026 Capital increase of €517,452.30 · to €16,919,988.10 · 10,422 new shares · in cash
- 11-02-2026 Capital reduction of €30,175,388 · to €17,535,111.80 · aanzuivering overgedragen verliezen
- 11-02-2026 Capital reduction of €1,132,576 · to €16,402,535.80 · to absorb losses
- 14-07-2025 Capital increase of €5,201,770 · to €47,710,499.80 · 14,309 new shares
- 30-12-2024 Capital increase of €5,199,589 · to €42,508,729.80 · 14,305 new shares
- 06-05-2024 Capital increase of €5,199,589 · to €37,309,140.80 · 14,305 new shares · “uitoefening van 14305 Inschrijvingsrechten”
- 19-04-2024 Capital increase of €4,960,351.80 · to €32,109,551.80 · 15,980 new shares
- 19-04-2024 Capital increase of €4,960,351.80 · 15,980 new shares